All Stories

  1. Risk stratification utilizing sequential organ failure assessment (SOFA) score, antithrombin activity, and demographic data in sepsis-associated disseminated intravascular coagulation (DIC)
  2. Defining heparin resistance: communication from the ISTH SSC Subcommittee of Perioperative and Critical Care Thrombosis and Hemostasis
  3. Mechanisms and management of the coagulopathy of trauma and sepsis: trauma-induced coagulopathy, sepsis-induced coagulopathy, and disseminated intravascular coagulation
  4. The antithrombin activity recovery after substitution therapy is associated with improved 28-day mortality in patients with sepsis-associated disseminated intravascular coagulation
  5. Persistent and Late-Onset Disseminated Intravascular Coagulation Are Closely Related to Poor Prognosis in Patients with Sepsis
  6. What Role Does Microthrombosis Play in Long COVID?
  7. A commentary on “Thromboinflammation in long COVID – the elusive key to post-infection sequelae?”
  8. Thromboinflammation in acute injury: infections, heatstroke, and trauma
  9. Super Formula for Diagnosing Disseminated Intravascular Coagulation Using Soluble C-Type Lectin-like Receptor 2
  10. What’s fishy about protamine? Clinical use, adverse reactions, and potential alternatives
  11. “Communication from the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis on sepsis-induced coagulopathy in the management of sepsis”: reply
  12. The pathophysiology, diagnosis, and management of sepsis-associated disseminated intravascular coagulation
  13. Thrombotic Mechanism Involving Platelet Activation, Hypercoagulability and Hypofibrinolysis in Coronavirus Disease 2019
  14. Communication from the Scientific Standardization Committees of the International Society on Thrombosis and Haemostasis on vascular endothelium-related biomarkers in disseminated intravascular coagulation
  15. Communication from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis on sepsis-induced coagulopathy in the management of sepsis
  16. Designing the Diagnostic Criteria for Disseminated Intravascular Coagulation (DIC)
  17. Disseminated Intravascular Coagulation: The Past, Present, and Future Considerations
  18. Intracellular communication and immunothrombosis in sepsis
  19. Morphological Changes in Blood Cells in a Rat Model of Heatstroke: A Pilot Study
  20. ISTH guidelines for antithrombotic treatment in COVID ‐19
  21. Thrombosis and thrombocytopenia in COVID-19 and after COVID-19 vaccination
  22. Elevated Plasma Soluble C-Type Lectin-like Receptor 2 Is Associated with the Worsening of Coronavirus Disease 2019
  23. Heatstroke-induced coagulopathy: Biomarkers, mechanistic insights, and patient management
  24. Nevertheless, the importance of coagulation abnormalities should be emphasized in international sepsis guidelines
  25. The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic thrombocytopenia
  26. Roles of Coagulation Abnormalities and Microthrombosis in Sepsis: Pathophysiology, Diagnosis, and Treatment
  27. Viral-Induced Inflammatory Coagulation Disorders: Preparing for Another Epidemic
  28. COVID‐19: Thrombosis, thromboinflammation, and anticoagulation considerations
  29. Soluble C-Type Lectin-Like Receptor 2 Is a Biomarker for Disseminated Intravascular Coagulation
  30. Endothelial Injury in COVID-19 and Acute Infections
  31. Managing thrombosis and cardiovascular complications of COVID-19: answering the questions in COVID-19-associated coagulopathy
  32. Diagnosis of Sepsis by AI-Aided Proteomics Using 2D Electrophoresis Images of Patient Serum Incorporating Transfer Learning for Deep Neural Networks
  33. Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered?
  34. Proposal of the Definition for COVID-19-Associated Coagulopathy
  35. Recent advances in the research and management of sepsis-associated DIC
  36. Editorial commentary: Vascular injury in acute infections and COVID-19: everything old is new again
  37. Newly Developed Recombinant Antithrombin Protects the Endothelial Glycocalyx in an Endotoxin-Induced Rat Model of Sepsis
  38. COVID‐19 coagulopathy in pregnancy: Critical review, preliminary recommendations, and ISTH registry—Communication from the ISTH SSC for Women’s Health
  39. The coagulopathy, endotheliopathy, and vasculitis of COVID-19
  40. ISTH DIC subcommittee communication on anticoagulation in COVID‐19
  41. Underlying disorders of disseminated intravascular coagulation: Communication from the ISTH SSC Subcommittees on Disseminated Intravascular Coagulation and Perioperative and Critical Care Thrombosis and Hemostasis
  42. Coagulopathy in COVID‐19
  43. The unique characteristics of COVID-19 coagulopathy
  44. RE: The prothrombin time ratio is not a more effective marker for evaluating sepsis‐induced coagulopathy than fibrin‐related markers: Response to the Letter‐to‐the‐Editor by Dr Wada
  45. Efficacy and safety of recombinant human soluble thrombomodulin in patients with sepsis‐associated coagulopathy: A systematic review and meta‐analysis
  46. Diagnosis and management of sepsis‐induced coagulopathy and disseminated intravascular coagulation
  47. The progression from coagulopathy to disseminated intravascular coagulation in representative underlying diseases
  48. DIC in obstetrics: Diagnostic score, highlights in management, and international registry‐communication from the DIC and Women's Health SSCs of the International Society of Thrombosis and Haemostasis
  49. Proposal of a two‐step process for the diagnosis of sepsis‐induced disseminated intravascular coagulation
  50. Current status of venous thromboembolism development during the perioperative period for colorectal cancer, its prevention with enoxaparin, and monitoring methods
  51. Sepsis-associated disseminated intravascular coagulation and its differential diagnoses
  52. The wind changed direction and the big river still flows: from EUPHRATES to TIGRIS
  53. Diagnosis of sepsis‐induced disseminated intravascular coagulation and coagulopathy
  54. Derangement of the endothelial glycocalyx in sepsis
  55. Differential diagnoses for sepsis‐induced disseminated intravascular coagulation: communication from the SSC of the ISTH
  56. Usefulness of Measuring Changes in SOFA Score for the Prediction of 28-Day Mortality in Patients With Sepsis-Associated Disseminated Intravascular Coagulation
  57. Oh, how hard it is to open the gate for sepsis trials: lessons from SCARLET
  58. Protection of the endothelial glycocalyx by antithrombin in an endotoxin-induced rat model of sepsis
  59. Role of extracellular vesicles in the development of sepsis-induced coagulopathy
  60. Prediction of Early Death in Patients With Sepsis-Associated Coagulation Disorder Treated With Antithrombin Supplementation
  61. Newly Proposed Sepsis-Induced Coagulopathy Precedes International Society on Thrombosis and Haemostasis Overt-Disseminated Intravascular Coagulation and Predicts High Mortality
  62. Sepsis-Induced Coagulopathy and Japanese Association for Acute Medicine DIC in Coagulopathic Patients with Decreased Antithrombin and Treated by Antithrombin
  63. Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis
  64. Modified DIC diagnostic criteria
  65. Efficacy and Bleeding Risk of Antithrombin Supplementation in Patients With Septic Disseminated Intravascular Coagulation: A Third Survey
  66. Physiological Levels of Pentraxin 3 and Albumin Attenuate Vascular Endothelial Cell Damage Induced by Histone H3In Vitro
  67. Prothrombin Time Tests for the Monitoring of Direct Oral Anticoagulants and Their Evaluation as Indicators of the Reversal Effect
  68. Antithrombin or thrombomodulin administration in severe pneumonia patients with sepsis and disseminated intravascular coagulation: comment on two papers
  69. Combination of antithrombin and recombinant thrombomodulin modulates neutrophil cell-death and decreases circulating DAMPs levels in endotoxemic rats
  70. Anticoagulant therapy for sepsis-associated disseminated intravascular coagulation: the view from Japan
  71. Rivaroxaban attenuates leukocyte adhesion in the microvasculature and thrombus formation in an experimental mouse model of type 2 diabetes mellitus
  72. Neutrophil extracellular traps, damage-associated molecular patterns, and cell death during sepsis
  73. The anticoagulant therapy for sepsis-associated disseminated intravascular coagulation
  74. Recombinant thrombomodulin improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat LPS model